Real world data shows that Stelara offers lower rates of psoriasis infection

27 March 2014

New interval findings from an international prospective disease-based registry provide a review of important patient outcomes related to systemic psoriasis treatments including Stelara (ustekinumab) from US health care giant Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen.

The prospective, disease-based Psoriasis Longitudinal Assessment and Registry (PSOLAR) study was designed to assess therapeutic risk and benefits in a population of patients with moderate to severe psoriasis, while also meeting the needs for post-marketing surveillance of biologics including those marketed by Janssen. The data were presented at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) in Denver, Colorado, USA.

Data collected over two years

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK